Study S002043

A Phase 1, Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ecnoglutide Tablet in Healthy Adult Participants

ClinicalTrials.gov record

Registration

Registration: NCT05184322
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 87
Start: 2022-04-12
Primary completion: 2024-07-13
Lead sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
Conditions: Obesity; Type 2 Diabetes Mellitus
Interventions: DRUG:T2026; DRUG:Placebo; DRUG:Oral ecnoglutide tablet
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number and percentage of treatment emergent adverse events (TEAEs) and serious adverse events (SAE) [Up to 98 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.